JCR Pharmaceuticals Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 7 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
952.9K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
599.8K | +8.38% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
382.7K | 0.00% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
238.6K | +17.08% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF
|
126.2K | -0.09% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Pacific Stock Index Fd.
|
81.8K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
10.9K | +1.00% |
Dividend History
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥20 | 0.0% |
| 2024 | ¥20 | 0.0% |
| 2023 | ¥20 | -9.1% |
| 2022 | ¥22 | +46.7% |
| 2021 | ¥15 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥51,082M | ¥34,343M | ¥42,871M | ¥33,072M |
| Gross Profit | ¥40,620M | ¥25,456M | ¥31,251M | ¥21,738M |
| Operating Income | ¥19,934M | ¥4,976M | ¥7,532M | -¥6,651M |
| Pretax Income | ¥19,449M | ¥5,456M | ¥7,330M | -¥6,259M |
| Net Income | ¥14,507M | ¥3,772M | ¥5,507M | -¥4,759M |
| EPS | ¥116.80 | ¥30.22 | ¥43.92 | - |
| Operating Margin | 39.02% | 14.49% | 17.57% | -20.11% |
| Balance Sheet | ||||
| Total Assets | ¥97,134M | ¥94,937M | ¥102,226M | ¥104,855M |
| Total Equity | ¥50,881M | ¥52,161M | ¥56,176M | ¥47,040M |
| Total Liabilities | ¥46,253M | ¥42,776M | ¥46,050M | ¥57,815M |
| Cash | ¥30,733M | ¥13,278M | ¥18,756M | ¥13,196M |
| Interest-bearing Debt | ¥18,100M | ¥22,800M | ¥23,300M | ¥38,105M |
| Equity Ratio | 52.38% | 54.94% | 54.95% | 44.86% |
| D/E Ratio | 0.36 | 0.44 | 0.41 | 0.81 |
| Cash Flow | ||||
| Operating CF | ¥9,289M | -¥5,500M | ¥9,312M | -¥5,486M |
| Investing CF | -¥3,250M | -¥15,002M | -¥2,690M | -¥9,874M |
| Financing CF | -¥2,179M | ¥1,948M | -¥2,031M | ¥9,736M |
| Free CF | -¥2,118M | -¥14,060M | ¥7,786M | -¥15,374M |
| Efficiency | ||||
| ROE | 28.51% | 7.23% | 9.80% | -10.12% |
| ROA | 14.94% | 3.97% | 5.39% | -4.54% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4552
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥675
Rating Score: 3.33 (Based on 7 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was founded in 1975 and is based in Ashiya, Japan.
